Hardy Z Kornfeld from Westport, MA, age 72

Dr. Hardy Kornfeld, Worcester MA - MD (Doctor of Medicine)

view source

Specialties:

Critical Care Medicine
Pulmonology

Address:

Umass Mem Med Ctr Pulomonlgy
55 Lake Ave N Suite Ha524, Worcester, MA 01655
7744432781 (Phone)

Certifications:

Critical Care Medicine, 1989
Internal Medicine, 1981
Pulmonary Disease, 1984

Awards:

Healthgrades Honor Roll

Languages:

English

Hospitals:

Umass Mem Med Ctr Pulomonlgy
55 Lake Ave N Suite Ha524, Worcester, MA 01655

UMass Memorial Medical Center - Memorial Campus
119 Belmont Street, Worcester, MA 01605

Education:

Medical School
Boston University School of Medicine
Graduated: 1978
Medical School
University Hospital/Boston
Graduated: 1978
Medical School
St Luke's Hospital Ny
Graduated: 1978
Medical School
University Hospital
Graduated: 1978
Medical School
Boston University Med Center
Graduated: 1978
Medical School
St Luke's Roosevelt Med Ctrny
Graduated: 1978

Hardy Kornfeld

view source

Specialties:

Pulmonary Critical Care Medicine

Work:

UMass Memorial Medical GroupUmass Memorial Medical Center Pulmonology
55 Lk Ave N STE HA524, Worcester, MA 01655
7744432781 (phone), 7744423999 (fax)

Education:

Medical School
Boston University School of Medicine
Graduated: 1978

Conditions:

Bronchial Asthma
Pneumonia

Languages:

English
Spanish

Description:

Dr. Kornfeld graduated from the Boston University School of Medicine in 1978. He works in Worcester, MA and specializes in Pulmonary Critical Care Medicine. Dr. Kornfeld is affiliated with UMASS Memorial Medical Center.

Hardy Kornfeld, Worcester MA

view source

Specialties:

Internal Medicine
Critical Care Medicine
Pulmonary Disease
Critical Care Medicine

Work:

U Mass Memorial Medical Center
55 Lake Ave N, Worcester, MA 01655

Education:

Boston University(1978)

Hardy Kornfeld, Worcester MA

view source

Specialties:

Pulmonologist

Address:

364 Plantation St, Worcester, MA 01605
55 Lake Ave N, Worcester, MA 01655

Education:

Boston University, School of Medicine - Doctor of Medicine

Board certifications:

American Board of Internal Medicine Certification in Internal Medicine
American Board of Internal Medicine Sub-certificate in Critical Care Medicine (Internal Medicine)
American Board of Internal Medicine Sub-certificate in Pulmonary Disease (Internal Medicine)

Us Patents

Il-16 Antagonist Peptides And Dna Encoding The Peptides
view source
US Patent:

6699466, Mar 2, 2004
Filed:

Aug 5, 1999
Appl. No.:

09/368630
Inventors:

David M. Center - Wellesley Hills MA
William W. Cruikshank - Westford MA
Hardy Kornfeld - Wellesley Hills MA
Assignee:

Research Corporation Technologies, Inc. - Tucson AZ
International Classification:

A61K 3807
US Classification:

424 852, 424 851, 514 2, 536 231, 536 235, 530300
Abstract:

The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acids in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16-mediated disorders such as certain inflammatory diseases.

Il-16 Antagonists
view source
US Patent:

6723697, Apr 20, 2004
Filed:

Aug 15, 2001
Appl. No.:

09/929922
Inventors:

David M. Center - Wellesley Hills MA
William W. Cruikshank - Westford MA
Hardy Kornfeld - Wellesley Hills MA
Assignee:

Research Corporation Technologies, Inc. - Tucson AZ
International Classification:

A61K 3800
US Classification:

514 2, 514 13, 514 14, 514 16, 514 17, 514 18, 530300
Abstract:

In accordance with the present invention, novel IL-16 antagonists, preferably peptides derived from CD4, have been isolated and synthesized. These peptides possess IL-16 antagonistic properties including the ability to selectively bind to IL-16 and inhibit IL-16-mediated biological activity. The peptides comprise specific portions of the native human CD4 receptor and variations thereof and therefore are non-immunogenic when administered to humans. The present invention also provides compositions containing at least one IL-16 antagonist peptide which can inhibit, suppress or cause the cessation of at least one IL-16-mediated biological activity in mammals, including humans. The present invention provides a method and composition for treating inflammation associated with disease states such as asthma, rheumatoid arthritis, inflammatory bowel disease (IBD) and systemic lupus (SLE) in mammals such as, for example, humans.

Il-16 Antagonists
view source
US Patent:

7019118, Mar 28, 2006
Filed:

Aug 15, 2001
Appl. No.:

09/929924
Inventors:

David M. Center - Wellesley Hills MA, US
William W. Cruikshank - Westford MA, US
Hardy Kornfeld - Wellesley Hills MA, US
Assignee:

Trustees of Boston University - Boston MA
International Classification:

C07K 16/00
C07K 14/00
A61K 39/395
US Classification:

5303871, 5303881, 5303891, 530324, 530350, 4241391
Abstract:

In accordance with the present invention, novel IL-16 antagonists, preferably peptides derived from CD4, have been isolated and synthesized. These peptides possess IL-16 antagonistic properties including the ability to selectively bind to IL-16 and inhibit IL-16-mediated biological activity. The peptides comprise specific portions of the native human CD4 receptor and variations thereof and therefore are non-immunogenic when administered to humans. The present invention also provides compositions containing at least one IL-16 antagonist peptide which can inhibit, suppress or cause the cessation of at least one IL-16-mediated biological activity in mammals, including humans. The present invention provides a method and composition for treating inflammation associated with disease states such as asthma, rheumatoid arthritis, inflammatory bowel disease (IBD) and systemic lupus (SLE) in mammals such as, for example, humans.

Il-16 Antagonist Peptides And Dna Encoding The Peptides
view source
US Patent:

7208149, Apr 24, 2007
Filed:

Feb 5, 2003
Appl. No.:

10/358627
Inventors:

David M. Center - Wellesley Hills MA, US
William W. Cruikshank - Westford MA, US
Hardy Kornfeld - Wellesley Hills MA, US
Assignee:

Trustees of Boston University - Boston MA
International Classification:

A61K 38/08
A61K 38/10
C07K 5/10
C07K 7/00
C07H 21/04
US Classification:

424 852, 514 16, 514 17, 530326, 530328, 530329, 530330, 536 235
Abstract:

The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acids in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases.

Il-16 Antagonists
view source
US Patent:

7232801, Jun 19, 2007
Filed:

Jun 27, 2005
Appl. No.:

11/167710
Inventors:

David M. Center - Wellesley Hills MA, US
William W. Cruikshank - Westford MA, US
Hardy Kornfeld - Wellesley Hills MA, US
Assignee:

Trustees of Boston University - Boston MA
International Classification:

A61K 38/08
A61K 38/04
A61K 38/00
A61K 45/00
C07K 7/06
US Classification:

514 14, 514 17, 530329, 424 851, 424 852
Abstract:

In accordance with the present invention, novel IL-16 antagonists, preferably peptides derived from CD4, have been isolated and synthesized. These peptides possess IL-16 antagonistic properties including the ability to selectively bind to IL-16 and inhibit IL-16-mediated biological activity. The peptides comprise specific portions of the native human CD4 receptor and variations thereof and therefore are non-immunogenic when administered to humans. The present invention also provides compositions containing at least one IL-16 antagonist peptide which can inhibit, suppress or cause the cessation of at least one IL-16-mediated biological activity in mammals, including humans. The present invention provides a method and composition for treating inflammation associated with disease states such as asthma, rheumatoid arthritis, inflammatory bowel disease (IBD) and systemic lupus (SLE) in mammals such as, for example, humans.

Antibodies Against Il-16 Antagonist Peptides
view source
US Patent:

7608691, Oct 27, 2009
Filed:

Oct 6, 2006
Appl. No.:

11/544055
Inventors:

David M. Center - Wellesley Hills MA, US
William W. Cruikshank - Westford MA, US
Hardy Kornfeld - Wellesley Hills MA, US
Assignee:

Trustees of Boston University - Boston MA
International Classification:

C07K 16/24
C07K 7/06
C07K 7/08
C07K 5/00
US Classification:

5303871, 5303879, 530300
Abstract:

The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acid in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases.

Methods Of Treatment Using Il-16 Antagonist Peptides
view source
US Patent:

7914778, Mar 29, 2011
Filed:

Mar 16, 2007
Appl. No.:

11/725090
Inventors:

David M. Center - Wellesley Hills MA, US
William W. Cruikshank - Westford MA, US
Hardy Kornfeld - Wellesley Hills MA, US
Assignee:

Trustees of Boston University - Boston MA
International Classification:

A61K 38/08
C07K 7/00
C07K 7/06
US Classification:

424 852, 530328, 530329, 514 16, 514 17
Abstract:

The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acids in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases.

Methods Of Treatment Using Il-16 Antagonist Peptides
view source
US Patent:

20110207679, Aug 25, 2011
Filed:

Feb 18, 2011
Appl. No.:

13/030201
Inventors:

David M. Center - Wellesley Hills MA, US
William W. Cruikshank - Westford MA, US
Hardy Kornfeld - Wellesley Hills MA, US
Assignee:

TRUSTEES OF BOSTON UNIVERSITY - Boston MA
International Classification:

A61K 38/07
C07K 5/00
C07H 21/00
C07K 16/18
A61P 29/00
A61P 11/06
A61P 19/02
A61P 1/00
A61P 25/28
US Classification:

514 219, 530330, 536 235, 5303879
Abstract:

The present invention has found that a series of peptides having sequences that substantially correspond to specific regions of the C-terminus of IL-16 can inhibit the activity of IL-16. The present invention has demonstrated that such IL-16-inhibiting peptides can be as short as 4 amino acid in length. Based on these discoveries, the present invention provides IL-16 antagonist peptides and the use thereof for the treatment of IL-16 mediated disorders such as certain inflammatory diseases.